4 transcripts
DVAX
Earnings call transcript
NASDAQ
2024 Q2
6 Aug 24
.
In the second quarter, we initiated a randomized active-controlled dose escalation multicenter Phase 1/2 trial to evaluate the safety, tolerability
DVAX
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
tolerability profile of the current market-leading product.
One of the unique advantages we believe of our CpG 1018 adjuvant is its safety
DVAX
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
-leading product.
One of the unique advantages we believe of our CpG 1018 adjuvant is its safety and tolerability profile, combined with its ability
DVAX
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
in June '22. In June, we presented results from a Phase I randomized active controlled adjuvant dose escalation trial to evaluate the safety, tolerability
- Prev
- 1
- Next